EU, Japan and DNDi highlight the importance of sustained investment in research and development of medical countermeasures
Safety Classified by Officially
A policy study session in Tokyo on 16 November brought together the European Commission, the European Union Delegation to Japan, the Ministry of Health, Labour and Welfare of Japan (MHLW), the Japanese Strategic Center of Biomedical Advanced Research and Development for Preparedness and Response (SCARDA) and the Drugs for Neglected Diseases initiative (DNDi) to discuss how sustained investment in R&D capacity and international partnerships strengthen preparedness for future infectious disease threats.
Preparing for future health emergencies starts long before an outbreak occurs. It means maintaining research capabilities, expertise and partnerships so that they are in place when new threats emerge.
This was the focus of a policy study session held in Tokyo on 16 November, attended by Laurent Muschel, Deputy Head of DG HERA. The event was hosted by DNDi in collaboration with DG HERA and the EU Delegation to Japan, bringing together perspectives from the European Commission, Japan and DNDi, with Japanese parliamentarians among the intended participants.
Dengue was used as a case study to explore the challenges ahead. While the disease remains a major concern in endemic regions, changing climate conditions and the spread of mosquito vectors are also making it increasingly relevant to Europe.
The session explored how the European Union and Japan are strengthening their research and development (R&D) capabilities in the field of medical countermeasures, and how international cooperation can help sustain these efforts. Both have developed strategies to improve the development and production of vaccines, therapeutics and diagnostics.
Discussions also focused on the importance of maintaining research capacity and international partnerships beyond periods of crisis. Research networks and collaboration with countries where diseases are endemic can ensure that research responds to real needs while strengthening preparedness worldwide.
This is an extract. The publication continues at the source.
© European Union — excerpt, reused under CC BY 4.0. Licence
Read the original at the source: https://health.ec.europa.eu/latest-updates/eu-japan-and-dndi-highlight-importance-sustained-investment-research-and-development-medical-2026-11-16_en This address stopped responding when last checked on November 16, 2026. The record below is what Officially captured.
Officially imported this from European Commission — DG Health and Food Safety’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Commission — DG Health and Food Safety — imported from official source
- Official source
- https://health.ec.europa.eu/node/2/rss_en RSS
- Imported
- November 16, 2026 19:30
- Versions
- 1 recorded
- Identity
-
https://health.ec.europa.eu/latest-updates/eu-japan-and-dndi-highlight-importance-susta...